150 related articles for article (PubMed ID: 34254347)
1. Assurance in vaccine efficacy clinical trial design based on immunological responses.
Callegaro A; Zahaf T; Tibaldi F
Biom J; 2021 Oct; 63(7):1434-1443. PubMed ID: 34254347
[TBL] [Abstract][Full Text] [Related]
2. Predictive probability of success using surrogate endpoints.
Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
[TBL] [Abstract][Full Text] [Related]
3. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
Cotterill A; Whitehead J
Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
[TBL] [Abstract][Full Text] [Related]
4. Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studies.
Callegaro A; Karkada N; Aris E; Zahaf T
Pharm Stat; 2023; 22(3):475-491. PubMed ID: 36606496
[TBL] [Abstract][Full Text] [Related]
5. Assurance calculations for planning clinical trials with time-to-event outcomes.
Ren S; Oakley JE
Stat Med; 2014 Jan; 33(1):31-45. PubMed ID: 23861270
[TBL] [Abstract][Full Text] [Related]
6. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
Ciarleglio MM; Arendt CD
Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
[TBL] [Abstract][Full Text] [Related]
7. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
Yang J; Li G; Yang D; Wu J; Wang J; Gao X; Liu P
BMC Med Res Methodol; 2024 Jan; 24(1):12. PubMed ID: 38233758
[TBL] [Abstract][Full Text] [Related]
8. Bayesian model selection techniques as decision support for shaping a statistical analysis plan of a clinical trial: an example from a vertigo phase III study with longitudinal count data as primary endpoint.
Adrion C; Mansmann U
BMC Med Res Methodol; 2012 Sep; 12():137. PubMed ID: 22962944
[TBL] [Abstract][Full Text] [Related]
9. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
10. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
11. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
Berchialla P; Zohar S; Baldi I
Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
[TBL] [Abstract][Full Text] [Related]
12. Robust Bayesian sample size determination in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2008 Jun; 27(13):2290-306. PubMed ID: 18205170
[TBL] [Abstract][Full Text] [Related]
13. Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpoint.
Quan H; Xu Z; Luo J; Paux G; Cho M; Chen X
Pharm Stat; 2023; 22(4):633-649. PubMed ID: 36866697
[TBL] [Abstract][Full Text] [Related]
14. Bayesian sample size calculation for estimation of the difference between two binomial proportions.
Pezeshk H; Nematollahi N; Maroufy V; Marriott P; Gittins J
Stat Methods Med Res; 2013 Dec; 22(6):598-611. PubMed ID: 21436190
[TBL] [Abstract][Full Text] [Related]
15. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
Trials; 2014 Feb; 15():68. PubMed ID: 24571662
[TBL] [Abstract][Full Text] [Related]
16. Ignorance is not bliss: Statistical power is not probability of trial success.
Zierhut ML; Bycott P; Gibbs MA; Smith BP; Vicini P
Clin Pharmacol Ther; 2016 Apr; 99(4):356-9. PubMed ID: 26331445
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Bayesian expected power via Bayesian bootstrap.
Liu F
Stat Med; 2018 Oct; 37(24):3471-3485. PubMed ID: 29938832
[TBL] [Abstract][Full Text] [Related]
18. Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study.
Walley RJ; Smith CL; Gale JD; Woodward P
Pharm Stat; 2015; 14(3):205-15. PubMed ID: 25865949
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
20. Practical experiences of adopting assurance as a quantitative framework to support decision making in drug development.
Crisp A; Miller S; Thompson D; Best N
Pharm Stat; 2018 Jul; 17(4):317-328. PubMed ID: 29635777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
